Which anti-thyroid drug has been shown to decrease the risk of ophthalmopathy in Graves disease?

Which anti-thyroid drug has been shown to decrease the risk of ophthalmopathy in Graves disease?

• A. Methimazole
• B. Propylthiouracil
• C. Radioactive iodine
• D. Propranolol

Answer: (A)

Graves ophthalmopathy is driven by autoimmune activity against the TSH receptor, with orbital inflammation linked to the overall thyroid autoimmune state. Controlling thyroid hormone production with an antithyroid drug can help modulate this autoimmune process. Methimazole works by inhibiting thyroid peroxidase, lowering thyroid hormone synthesis, and it may also reduce the activity of thyroid-stimulating antibodies that fuel orbital inflammation. This combination tends to translate into a lower risk of ophthalmopathy progression compared with modalities that deliver thyroid ablation or rapid hormonal shifts, such as radioactive iodine, which can worsen eye disease in some patients. Propranolol provides symptomatic relief for hyperthyroid symptoms but does not impact the underlying autoimmune process, and propylthiouracil has similar thyroid-lowering effects but is less clearly protective for the eyes and carries greater risk of serious liver toxicity. Therefore, methimazole is the anti-thyroid drug most associated with a decreased risk of ophthalmopathy in Graves disease.

Graves ophthalmopathy is driven by autoimmune activity against the TSH receptor, with orbital inflammation linked to the overall thyroid autoimmune state. Controlling thyroid hormone production with an antithyroid drug can help modulate this autoimmune process. Methimazole works by inhibiting thyroid peroxidase, lowering thyroid hormone synthesis, and it may also reduce the activity of thyroid-stimulating antibodies that fuel orbital inflammation. This combination tends to translate into a lower risk of ophthalmopathy progression compared with modalities that deliver thyroid ablation or rapid hormonal shifts, such as radioactive iodine, which can worsen eye disease in some patients. Propranolol provides symptomatic relief for hyperthyroid symptoms but does not impact the underlying autoimmune process, and propylthiouracil has similar thyroid-lowering effects but is less clearly protective for the eyes and carries greater risk of serious liver toxicity. Therefore, methimazole is the anti-thyroid drug most associated with a decreased risk of ophthalmopathy in Graves disease.